Sanofi Consumer Healthcare India Appoints New CFO Amid Strong Q2 Performance Aug 04, 2025
Sanofi Consumer Healthcare India Reports Strong Q1 Results with 28% Revenue Growth Aug 04, 2025
Sanofi Consumer Healthcare India Reports Mixed Q4 Results Amid Product Recalls May 02, 2025
More news about Sanofi Consumer Healthcare
25Apr 25
Sanofi Consumer Healthcare Faces Potential 26% Stake Acquisition by Opal Bidco Sas and Clayton, Dubilier & Rice Fund
Opal Bidco Sas, with Clayton, Dubilier & Rice Fund XII, L.P., has announced an open offer to acquire up to 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer, made to public shareholders, complies with SEBI regulations. Key dates include the public announcement on October 21, 2024, and the final letter of offer issuance on April 12, 2025. This potential ownership shift could significantly impact the company's strategic direction and the Indian pharmaceutical market.
24Apr 25
Opal Bidco SAS Proposes 26% Stake Acquisition in Sanofi Consumer Healthcare India
Opal Bidco SAS, in association with Clayton, Dubilier & Rice Fund, has announced an open offer to acquire a 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer timeline spans from October 21, 2024, to April 24, 2025, with key events including public announcements, detailed statements, and letter of offer issuance. This move could potentially impact the company's strategic direction and operations, and is being conducted in compliance with SEBI regulations.
Sanofi Consumer Healthcare India Limited (SCHIL) has declared a final dividend of ₹55 per equity share for FY2024, subject to shareholder approval. The company reported total income of ₹7,375 million and net profit of ₹1,810 million for the year ended December 31, 2024. Revenue from operations grew by 30.4% to ₹7,245 million. SCHIL completed its demerger from Sanofi India Limited and listed on NSE and BSE in September 2024. The company voluntarily recalled Allegra and Combiflam Suspensions in July 2024 as a precautionary measure.
Sanofi Consumer Healthcare India Limited (SCHIL) reported a significant downturn in its Q4 2024 financial results. Revenue decreased by 24% to ₹170.7 crore, while net profit fell by 34.8% to ₹44.3 crore compared to Q4 2023. EBITDA also declined by 30.6% to ₹61.1 crore, with margins contracting to 36.4%. Despite the challenging quarter, the company declared a final dividend of ₹55 per share for FY2024, subject to shareholder approval.